Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Busulfan liposomal - Calliditas Therapeutics

Next Previous
Search
Drug Profile

Busulfan liposomal - Calliditas Therapeutics

Alternative Names: Busulipo; MZH-2

Latest Information Update: 12 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karolinska Institute
  • Developer Calliditas Therapeutics
  • Class Antineoplastics; Butylene glycols; Glycols; Mesylates; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents; DNA synthesis inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone marrow transplant rejection
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Bone marrow transplant rejection

Most Recent Events

  • 12 Mar 2025 Discontinued - Phase-II for Bone marrow transplant rejection (Prevention) in Sweden (IV), before March 2025 (Calliditas Therapeutics pipeline, March 2025)
  • 24 Sep 2020 No development reported - Phase-II for Bone marrow transplant rejection (Prevention) in Sweden (IV) (Calliditas Therapeutics website, September 2020)
  • 04 Jan 2012 Pharmalink completes phase II trials in Cancer as a myeloablative agent in Sweden

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top